Key takeaways
- • Trial: SURPASS-1 (NCT03954834) — Phase 3, 478 participants over 40 weeks.
- • Drug studied: Mounjaro (Tirzepatide) — FDA-approved branded product.
- • Primary endpoint: Change in HbA1c from baseline to week 40 in drug-naive adults with type 2 diabetes
- • Key result: HbA1c reduction 1.87% (5mg), 1.89% (10mg), and 2.07% (15mg) on tirzepatide vs +0.04% on placebo
- • Published: The Lancet, 2021.
Study design
SURPASS-1 was a phase 3 randomized controlled trial enrolling 478 participants over 40 weeks. The trial studied Mounjaro (Tirzepatide) for type 2 diabetes and was published in The Lancet in 2021.
Primary endpoint
Change in HbA1c from baseline to week 40 in drug-naive adults with type 2 diabetes
Key results
| Measure | Value |
|---|---|
| Headline result | HbA1c reduction 1.87% (5mg), 1.89% (10mg), and 2.07% (15mg) on tirzepatide vs +0.04% on placebo |
| HbA1c reduction (highest dose arm) | -2.07 percentage points |
| Participants | 478 |
| Duration | 40 weeks |
| Phase | Phase 3 |
Citation
SURPASS-1. Published in The Lancet, 2021.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Mounjaro drug page — pricing, FDA status, side effects, alternatives
- All tirzepatide trials
- GLP-1 clinical trials database
Other Mounjaro trials
Other Tirzepatide trials
- SURMOUNT-1 (Zepbound) — Mean weight loss 15
- SURMOUNT-2 (Zepbound) — Mean weight loss 12
- SURMOUNT-3 (Zepbound) — Additional 18
- SURMOUNT-4 (Zepbound) — Continued tirzepatide arm lost additional 5
Important: This trial was conducted on the FDA-approved branded product Mounjaro. Compounded versions of Tirzepatide have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.